Defence Therapeutics CEO outlines three strategic priorities in letter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St bounces as oil cools, inflation risks keeps Fed in focus
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for sharp weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
September 8, 2026 3:17 AM EDTMontreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc.(CSE: DTC) (OTCQB: DTCFF) (FSE: DTC)("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company's path forward.
Dear Shareholders,
Defence Therapeutics is entering an exciting new stage in... More
